LGMN and osteoporosis: R13 not only represses AEP expression through blunting its upstream transcription factor C/EBPβ but also blocks AEP activation via BDNF/TrkB pathway-activated Akt and it displays promising therapeutic efficacy toward osteoporosis which is similar to anti-RANKL antibody.